CY-09
CY-09 Basic information
- Product Name:
- CY-09
- Synonyms:
-
- CY-09
- 4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid
- CS-2756
- 4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid
- CY09;CY 09;CY-09
- CY 09;CY09
- (E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid
- Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]-
- CAS:
- 1073612-91-5
- MF:
- C19H12F3NO3S2
- MW:
- 423.43
- Mol File:
- 1073612-91-5.mol
More
Less
CY-09 Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO:65.0(Max Conc. mg/mL);152.61(Max Conc. mM)
- form
- A crystalline solid
- color
- Light yellow to yellow
More
Less
CY-09 Usage And Synthesis
Uses
CY-09, exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). CY-09 is an NLRP3 inhibitor.
Biological Activity
CY-09 is an NLRP3 inflammasone inhibitor. CY-09 binds directly to the ATP-binding motif of NLRP3 NACHT domain and inhibits its ATPase activity, blocking NLRP3 inflammasome assembly and activation. In mouse models CY-09 showed therapeutic effects in type 2 diabetes and cryopyrin-associated auto-inflammatory syndrome (CAPS), which is caused by gain-of-function mutations of NLRP3.
storage
Store at +4°C
CY-09Supplier
Accela ChemBio Co.,Ltd.
- Tel
- 021-50795510 4000665055
- sales@accelachem.com
SHANGHAI FORTUNE CHEMICAL TECHNOLOGY CO., LTD
- Tel
- 13816107857
- sales@fortunechem-sh.com
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
Shanghai EFE Biological Technology Co., Ltd.
- Tel
- 021-65675885 18964387627
- info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com